{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:34:24Z","timestamp":1789094064932,"version":"build-2803163510"},"reference-count":142,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaci.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T13:37:26Z","timestamp":1633441046000},"page":"911-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition"],"prefix":"10.1016","volume":"148","author":[{"given":"Yiming","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gadina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Meylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-8438","authenticated-orcid":false,"given":"Daniella M.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.08.004_bib1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2021.08.004_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjd.18634","article-title":"Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis","volume":"183","author":"Diels","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.08.004_bib8","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: Jak-STAT signaling II","volume":"181","author":"Villarino","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2021.08.004_bib9","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2021.08.004_bib10","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-020-18925-4","article-title":"Early-onset autoimmunity associated with SOCS1 haploinsufficiency","volume":"11","author":"Hadjadj","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.08.004_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1056\/NEJMoa1905633","article-title":"JAK inhibitor therapy in a child with inherited USP18 deficiency","volume":"382","author":"Alsohime","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib14","doi-asserted-by":"crossref","first-page":"13992","DOI":"10.1038\/ncomms13992","article-title":"Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection","volume":"7","author":"Eletto","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.08.004_bib15","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.immuni.2020.07.006","article-title":"Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function","volume":"53","author":"Gruber","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.08.004_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.jaci.2019.10.030","article-title":"Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression","volume":"145","author":"Mucha","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib18","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/art.40216","article-title":"Genome-wide association meta-analysis reveals novel juvenile idiopathic arthritis susceptibility loci","volume":"69","author":"McIntosh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.08.004_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nbt.3966","article-title":"Analysis of somatic microsatellite indels identifies driver events in human tumors","volume":"35","author":"Maruvka","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2021.08.004_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jaci.2021.08.004_bib22","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1182\/blood-2016-02-698951","article-title":"Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia","volume":"128","author":"Kapralova","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.08.004_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2021.08.004_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2021.08.004_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jaci.2021.08.004_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.08.004_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.gene.6363802","article-title":"Unexpected and variable phenotypes in a family with JAK3 deficiency","volume":"2","author":"Frucht","year":"2001","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaci.2021.08.004_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-142078","article-title":"Germline gain-of-function JAK3 mutation in familial chronic lymphoproliferative disorder of NK cells","volume":"136","author":"Lesmana","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.08.004_bib29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3389\/fimmu.2017.01824","article-title":"An activating Janus kinase-3 mutation is associated with cytotoxic T lymphocyte antigen-4-dependent immune dysregulation syndrome","volume":"8","author":"Sic","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.08.004_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fped.2020.00253","article-title":"A TYK2 gene mutation c.2395G>A leads to TYK2 deficiency: a case report and literature review","volume":"8","author":"Wu","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2021.08.004_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8714","article-title":"Tuberculosis and impaired IL-23-dependent IFN-gamma immunity in humans homozygous for a common TYK2 missense variant","volume":"3","author":"Boisson-Dupuis","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib33","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4049\/jimmunol.1203118","article-title":"Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent","volume":"190","author":"Li","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib34","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1038\/s41598-018-25260-8","article-title":"Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia","volume":"8","author":"Nemoto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2021.08.004_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/leu.2016.277","article-title":"Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences","volume":"31","author":"Waanders","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.08.004_bib37","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib38","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3390\/genes11121434","article-title":"TYK2 variants in B-acute lymphoblastic leukaemia","volume":"11","author":"Turrubiartes-Martinez","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jaci.2021.08.004_bib39","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.30455","article-title":"Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors","volume":"123","author":"Hirbe","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2021.08.004_bib40","article-title":"Clinical relevance of gain- and loss-of-function germline mutations in STAT1: a systematic review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib41","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1002\/eji.201445344","article-title":"Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)","volume":"45","author":"Zheng","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib42","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1073\/pnas.1220098110","article-title":"STAT2 deficiency and susceptibility to viral illness in humans","volume":"110","author":"Hambleton","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2021.08.004_bib43","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.jaci.2016.10.033","article-title":"A novel kindred with inherited STAT2 deficiency and severe viral illness","volume":"139","author":"Moens","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib44","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awv182","article-title":"Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission","volume":"138","author":"Shahni","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.jaci.2021.08.004_bib45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192319","article-title":"Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy","volume":"217","author":"Gruber","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav7501","article-title":"Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2","volume":"4","author":"Duncan","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.iac.2018.08.007","article-title":"An update on syndromes with a hyper-IgE phenotype","volume":"39","author":"Bergerson","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2021.08.004_bib48","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jaip.2019.02.018","article-title":"Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review","volume":"7","author":"Fabre","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.08.004_bib49","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/leu.2012.350","article-title":"STAT3 mutations are highly specific for large granular lymphocytic leukemia","volume":"27","author":"Fasan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.08.004_bib50","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2016-09-737817","article-title":"Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea","volume":"129","author":"Ma","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.08.004_bib51","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/infdis\/jix522","article-title":"Paracoccidioidomycosis associated with a heterozygous STAT4 mutation and impaired IFN-gamma immunity","volume":"216","author":"Schimke","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib52","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/ofid\/ofz359.166","article-title":"2888. STAT4 mutation in three generations with disseminated coccidioidomycosis (DCM) also exhibits increased susceptibility to coccidioidal infection in transfected mice","volume":"6","author":"Powell","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib53","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1212\/WNL.94.15_supplement.4414","article-title":"Progressive multifocal leukoencephalopathy associated with idiopathic CD4+ lymphocytopenia in a patient with heterozygous STAT4 mutation (4414)","volume":"94","author":"Acarli","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2021.08.004_bib54","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/infdis\/jiu667","article-title":"Whole-genome sequencing identifies STAT4 as a putative susceptibility gene in classic Kaposi sarcoma","volume":"211","author":"Aavikko","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib55","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/cas.13525","article-title":"Mutations in the signal transducer and activator of transcription family of genes in cancer","volume":"109","author":"Shahmarvand","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jaci.2021.08.004_bib56","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/ard.2008.097642","article-title":"STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk","volume":"68","author":"Abelson","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib57","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2017-212794","article-title":"The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-gamma production in T cells from patients with SLE","volume":"77","author":"Hagberg","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib58","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.08.004_bib59","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41467-018-04521-0","article-title":"Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation","volume":"9","author":"Klammt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.08.004_bib60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.08.004_bib61","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.08.004_bib62","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaip.2020.11.050","article-title":"JAK inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease","volume":"9","author":"Eisenberg","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.08.004_bib63","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","article-title":"Activating STAT6 mutations in follicular lymphoma","volume":"125","author":"Yildiz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.08.004_bib64","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.08.004_bib65","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jaci.2012.03.012","article-title":"STAT6 and LRP1 polymorphisms are associated with food allergen sensitization in Mexican children","volume":"129","author":"Hancock","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/gene.2008.2","article-title":"A STAT6 gene polymorphism is associated with high infection levels in urinary schistosomiasis","volume":"9","author":"He","year":"2008","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaci.2021.08.004_bib67","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/sj.gene.6364030","article-title":"An asthma-associated genetic variant of STAT6 predicts low burden of ascaris worm infestation","volume":"5","author":"Peisong","year":"2004","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaci.2021.08.004_bib68","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib69","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.08.004_bib71","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2021.08.004_bib72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-018-1541-z","article-title":"Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes","volume":"20","author":"Genovese","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2021.08.004_bib73","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib74","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib75","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib76","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.004_bib77","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib78","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.004_bib79","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2021.08.004_bib80","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib81","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib82","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib83","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib84","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib85","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib86","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib87","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.004_bib88","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib89","first-page":"72","article-title":"Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial","author":"Mease","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib90","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib91","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib92","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib93","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaci.2021.08.004_bib94","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2021.08.004_bib95","article-title":"The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"258","author":"Akbari","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.jaci.2021.08.004_bib96","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib97","series-title":"Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19","year":"2020"},{"key":"10.1016\/j.jaci.2021.08.004_bib98","series-title":"NIH closes enrollment in trial comparing COVID-19 treatment regimens","year":"2021"},{"key":"10.1016\/j.jaci.2021.08.004_bib99","doi-asserted-by":"crossref","unstructured":"Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et\u00a0al. Baricitinib plus standard of care for hospitalized adults with COVID-19 [published online ahead of print May 3, 2021]. medRxiv. doi: https:\/\/doi.org\/10.1101\/2021.04.30.21255934","DOI":"10.1101\/2021.04.30.21255934"},{"key":"10.1016\/j.jaci.2021.08.004_bib100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimaraes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102726","article-title":"Combined anakinra and ruxolitinib treatment to rescue extremely ill COVID-19 patients: a pilot study","volume":"20","author":"Kaplanski","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2021.08.004_bib102","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.004_bib103","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib104","doi-asserted-by":"crossref","unstructured":"Hasni S, Gupta S, Davis MA, Poncio E, Temesgen-Oyelakin Y, Biehl A, et\u00a0al. 183 A phase 1B\/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus. Abstracts 2019:A139.2-A40.","DOI":"10.1136\/lupus-2019-lsm.183"},{"key":"10.1016\/j.jaci.2021.08.004_bib105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib106","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib107","doi-asserted-by":"crossref","unstructured":"Kim H, Dill S, O\u2019Brien M, Vian L, Li X, Manukyan M, et\u00a0al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis [published online ahead of print August 25, 2020]. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218690.","DOI":"10.1136\/annrheumdis-2020-218690"},{"key":"10.1016\/j.jaci.2021.08.004_bib108","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib109","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.08.004_bib110","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus Kinase inhibition in the Aicardi-Goutieres syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib111","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/annrheumdis-2019-215918","article-title":"Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20","volume":"79","author":"Schwartz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib112","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib113","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.004_bib114","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.004_bib115","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.004_bib116","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib117","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib118","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","article-title":"Signaling by IL-31 and functional consequences","volume":"91","author":"Cornelissen","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.jaci.2021.08.004_bib119","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2021.01.020","article-title":"Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy","volume":"10","author":"Peterson","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2021.08.004_bib120","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib121","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2021.08.004_bib122","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2017-10-812701","article-title":"Phase 1 study of the PI3Kdelta inhibitor INCB040093\u00a0+\/\u2212 JAK1 inhibitor itacitinib in relapsed\/refractory B-cell lymphoma","volume":"132","author":"Phillips","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.08.004_bib123","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/cam4.2042","article-title":"Persistent Janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: results of a phase I trial","volume":"8","author":"Spaner","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib124","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-19-1899","article-title":"A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Berenson","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2021.08.004_bib125","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cam4.1703","article-title":"Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed\/refractory metastatic colorectal cancer","volume":"7","author":"Fogelman","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.jaci.2021.08.004_bib126","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10549-018-4770-6","article-title":"A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation","volume":"170","author":"O\u2019Shaughnessy","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaci.2021.08.004_bib127","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaci.2021.08.004_bib128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.08.004_bib129","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2013.167","article-title":"AKT is\u00a0a\u00a0therapeutic target in myeloproliferative neoplasms","volume":"27","author":"Khan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.08.004_bib130","doi-asserted-by":"crossref","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.jaci.2021.08.004_bib131","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.08.004_bib132","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10637-019-00794-4","article-title":"Cotargeting the JAK\/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms","volume":"38","author":"Hao","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaci.2021.08.004_bib133","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2021.08.004_bib134","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib136","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","article-title":"Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program","volume":"44","author":"Conaghan","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaci.2021.08.004_bib137","article-title":"Pooled safety analyses from phase 3 studies of filgotinib in patients with rheumatoid arthritis","volume":"71","author":"Winthrop","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib138","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.004_bib140","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.004_bib141","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40264-018-0639-1","article-title":"Gastrointestinal perforations with biologics in patients with rheumatoid arthritis: implications for clinicians","volume":"41","author":"Jagpal","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaci.2021.08.004_bib142","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001565","article-title":"RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?","volume":"7","author":"Strand","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2021.08.004_bib143","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment\u00a0discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaci.2021.08.004_bib144","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fonc.2019.00048","article-title":"Signal transducer and activator of transcription (STATs) proteins in cancer and\u00a0inflammation: functions and therapeutic implication","volume":"9","author":"Loh","year":"2019","journal-title":"Front Oncol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921012422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921012422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:32:13Z","timestamp":1758792733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921012422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0091674921012422"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.004","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}